PNC-27 — Clinical Reference (Investigational, Preclinical)

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction PNC-27 is an investigational chimeric peptide developed in the Pincus and Michl laboratory, combining a p53-derived HDM-2 binding domain with a membrane-residence/penetrating sequence. **Strictly preclinical**; PNC-27 is not approved by any major regulatory agency for clinical use, and clinical-grade efficacy and safety data for humans are not established. ## Mechanism of Action In preclinical work, PNC-27 is reported to interact with HDM-2 expressed at the plasma membrane of cancer cells, leading to selective membranolysis of cancer cells while sparing normal cells. The proposed mechanism is necrotic membrane disruption rather than classical apoptotic signaling. Mechanistic claims continue to be evaluated and debated in the peer-reviewed literature. ## Research Indications Preclinical models of pancreatic, leukemic, and breast cancers. **No completed phase 2 or phase 3 clinical trials with externally replicable efficacy outcomes in humans exist.** PNC-27 is not a substitute for any standard-of-care oncologic therapy. ## Reconstitution **Not applicable for clinical or self-directed use.** PNC-27 should only be reconstituted and used within an IRB-approved formal research protocol with institutional oversight. No standardized human-grade reconstitution or dosing protocol exists in the peer-reviewed literature. ## Dosing Protocol **No human-grade dosing has been established.** Preclinical animal protocols are not appropriate for direct human extrapolation given the unresolved questions about pharmacokinetics, off-target membranolysis, and systemic safety. **Do not use outside formal research protocols.** ## Administration Not applicable for clinical or self-directed use. Preclinical animal studies have used IV, IP, and SC routes; human equivalents are not established. ## Storage & Handling Not applicable outside a research-protocol context. If procured for IRB-approved research: refrigerate lyophilized, freeze (–20°C) for long-term storage, and follow protocol-specific reconstitution and stability instructions. ## Side Effects Human safety data are not established. Theoretical concerns include off-target membranolysis, cytokine release on rapid tumor lysis, immunogenicity of the peptide, and unpredictable interactions with concurrent oncologic therapy. ## Contraindications **All clinical use outside an IRB-approved research protocol.** Never use as a substitute for or in lieu of oncologist-directed standard-of-care treatment. ## Monitoring Standard oncology surveillance (imaging, tumor markers, organ-function panels) would apply within any IRB-approved trial. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.